Public Offerings
- Advising companies such as Rubius Therapeutics, Fleetmatics, Mimecast, bluebird bio, Neos Therapeutics, Jounce Therapeutics and Opower and investment banks such as Goldman Sachs and Morgan Stanley on executive compensation disclosure requirements
M&A – Executive Compensation
- Qualtrics International Inc. in its $8 billion sale to SAP SE
- Keryx Biopharmaceuticals, Inc. in connection with its merger with Akebia Therapeutics, Inc.
- Foundation Medicine, Inc. in connection with its merger with Roche at an enterprise valuation of $5.3 billion
- Juniper Pharmaceuticals in its sale to Catalent
- Fleetmatics in its $2.4 billion sale to Verizon
- Lionbridge in its sale to HIG
- Opower in its sale to Oracle
- Ocata Therapeutics in its sale to Astellas Pharma
- Onyx Pharmaceuticals in its $10 billion sale to Amgen
- Fleetmatics in its acquisition of SageQuest
Ongoing Public Company Representation
- iRobot, Wayfair, Rubius Therapeutics, Mimecast, bluebird bio, Brightcove, GTT Communications, WisdomTree Investments, Assembly Biosciences, Viveve, Cedar Realty Trust, Empire State Realty Trust, Medical Properties Trust
